• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.干扰素 β-1A 给药与复发缓解型多发性硬化患者颅内血管张力调节的关系：一项初步研究。
Biomed Res Int. 2017;2017:5421416. doi: 10.1155/2017/5421416. Epub 2017 Sep 13.
2
Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.肌内注射干扰素β-1a 的长期疗效和安全性：两种剂量方案在日本复发缓解型多发性硬化症患者中的随机上市后试验。
Mult Scler Relat Disord. 2016 May;7:102-8. doi: 10.1016/j.msard.2016.02.002. Epub 2016 Feb 2.
3
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.肌肉注射干扰素β-1a对复发缓解型多发性硬化症脊髓体积的影响。
BMC Med Imaging. 2016 Oct 5;16(1):56. doi: 10.1186/s12880-016-0158-4.
4
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.干扰素β-1a（安万特）作为未经治疗的多发性硬化症患者的一种治疗选择（AXIOM）：一项前瞻性观察研究。
Int J Mol Sci. 2015 Jul 6;16(7):15271-86. doi: 10.3390/ijms160715271.
5
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.奥瑞珠单抗与皮下注射干扰素β-1a治疗复发型多发性硬化症的成本效益分析。
J Med Econ. 2017 Oct;20(10):1056-1065. doi: 10.1080/13696998.2017.1355310. Epub 2017 Jul 31.
6
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.侧向切换至 IFN beta-1a 44 mcg 可能与 fingolimod 一样有效，适用于在特定复发缓解型多发性硬化症患者中进行升级治疗：来自真实世界环境的经验。
Expert Rev Clin Pharmacol. 2018 May;11(5):531-536. doi: 10.1080/17512433.2018.1449643. Epub 2018 Mar 13.
7
Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?皮下注射干扰素β-1a相关血栓性微血管病的病例报告：一种新出现的并发症？
Neurologia. 2016 Sep;31(7):508-9. doi: 10.1016/j.nrl.2014.09.008. Epub 2014 Nov 11.
8
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.在EVIDENCE研究中，接受β-1a干扰素治疗的多发性硬化症患者的早期MRI结果及达到“无疾病活动证据”状态的几率。
J Neurol Sci. 2017 Aug 15;379:151-156. doi: 10.1016/j.jns.2017.05.052. Epub 2017 May 25.
9
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.达克珠单抗与干扰素β-1a对复发缓解型多发性硬化症患者报告结局的影响。
Mult Scler Relat Disord. 2017 Jan;11:18-24. doi: 10.1016/j.msard.2016.11.005. Epub 2016 Nov 13.
10
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.GSK239512与安慰剂对复发缓解型多发性硬化症患者的病灶再髓鞘化活性：一项随机、单盲、II期研究。
J Neurol. 2017 Feb;264(2):304-315. doi: 10.1007/s00415-016-8341-7. Epub 2016 Nov 25.

引用本文的文献

1
[Reversible cerebral vasoconstriction syndrome. Recurrence of thunderclap headaches after treatment with corticosteroids].[可逆性脑血管收缩综合征。皮质类固醇治疗后霹雳样头痛复发]
Rev Neurol. 2024 Jul 16;79(2):67-70. doi: 10.33588/rn.7902.2024167.
2
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications.多发性硬化症中的脑出血：评估疾病修正药物的影响。
Eur J Med Res. 2024 Jun 25;29(1):344. doi: 10.1186/s40001-024-01945-x.
3
Pharmacological treatments of COVID-19.COVID-19 的药物治疗。
Pharmacol Rep. 2020 Dec;72(6):1446-1478. doi: 10.1007/s43440-020-00152-9. Epub 2020 Aug 20.

本文引用的文献

1
Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.干扰素在复发缓解型多发性硬化症中的比较疗效：一项真实世界研究的荟萃分析
Curr Med Res Opin. 2017 Mar;33(3):579-593. doi: 10.1080/03007995.2016.1276895. Epub 2017 Jan 11.
2
Evolving concepts in the treatment of relapsing multiple sclerosis.多发性硬化症复发治疗中不断演变的理念。
Lancet. 2017 Apr 1;389(10076):1347-1356. doi: 10.1016/S0140-6736(16)32388-1. Epub 2016 Nov 24.
3
Multiple sclerosis: experimental models and reality.多发性硬化症：实验模型与现实。
Acta Neuropathol. 2017 Feb;133(2):223-244. doi: 10.1007/s00401-016-1631-4. Epub 2016 Oct 20.
4
Epidemiology of Multiple Sclerosis.多发性硬化症的流行病学
Neurol Clin. 2016 Nov;34(4):919-939. doi: 10.1016/j.ncl.2016.06.016. Epub 2016 Aug 18.
5
Transcranial Doppler ultrasonography: From methodology to major clinical applications.经颅多普勒超声检查：从方法学至主要临床应用
World J Cardiol. 2016 Jul 26;8(7):383-400. doi: 10.4330/wjc.v8.i7.383.
6
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.与用于治疗多发性硬化症的β-1a干扰素使用相关的可逆性脑血管收缩综合征
Mult Scler. 2016 Oct;22(12):1626-1628. doi: 10.1177/1352458516641774. Epub 2016 Mar 24.
7
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.干扰素β-1a治疗复发缓解型多发性硬化症疗效的免疫学和磁共振成像标志物
Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.
8
Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?干扰素β相关的肺动脉高压；一个新出现的令人担忧的病症？
Mult Scler Relat Disord. 2015 May;4(3):284-6. doi: 10.1016/j.msard.2015.03.008. Epub 2015 Apr 14.
9
Reversible Cerebral Vasoconstriction Syndrome, Part 2: Diagnostic Work-Up, Imaging Evaluation, and Differential Diagnosis.可逆性脑血管收缩综合征，第二部分：诊断检查、影像学评估及鉴别诊断
AJNR Am J Neuroradiol. 2015 Sep;36(9):1580-8. doi: 10.3174/ajnr.A4215. Epub 2015 Jan 22.
10
Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.β干扰素具有血管收缩和促凝血作用：一名女性在接受β干扰素治疗多发性硬化症时出现了网状青斑和雷诺现象。
Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S79-81. doi: 10.1016/j.clineuro.2013.09.027.

干扰素 β-1A 给药与复发缓解型多发性硬化患者颅内血管张力调节的关系：一项初步研究。

Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.

机构信息

IRCCS Centro Neurolesi "Bonino Pulejo", Via P.le Palermo S.S. 113, 98124 Messina, Italy.

Department of Human Pathology, University Hospital of Messina, Via Consolare Valeria, Messina, Italy.

出版信息

Biomed Res Int. 2017;2017:5421416. doi: 10.1155/2017/5421416. Epub 2017 Sep 13.

DOI:10.1155/2017/5421416
PMID:29057262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5615979/
Abstract

Interferon beta (IFN-) therapy is one of the most commonly prescribed immunomodulatory therapies in relapsing-remitting multiple sclerosis (RRMS). A reversible cerebral vasoconstriction syndrome (RCVS), associated with IFN- use, has been recently described. For this reason, we tested the effect of once a week intramuscular administration of IFN--1A on the function of cerebral vessels in a cohort of RRMS patients. Using transcranial Doppler (TCD) ultrasound, we measured the mean blood flow velocity (MFV) in intracranial vessels 10 h after IFN- administration. Measurements showed a significant increase in MFV compared to the baseline values in some vessels.

摘要

干扰素β（IFN-β）治疗是复发缓解型多发性硬化症（RRMS）中最常开的免疫调节治疗之一。最近描述了一种与 IFN-β 使用相关的可逆性脑动脉收缩综合征（RCVS）。因此，我们在一组 RRMS 患者中测试了每周一次肌肉注射 IFN-β1A 对脑血管功能的影响。我们使用经颅多普勒（TCD）超声在 IFN-β 给药后 10 小时测量颅内血管的平均血流速度（MFV）。测量结果显示，与基线值相比，一些血管的 MFV 显著增加。